Literature DB >> 8223767

Dosimetry of iodine-123 iodobenzamide in healthy volunteers.

N P Verhoeff1, E B Sokole, M Stabin, D Hengst, H F Kung, E A Van Royen, A G Janssen.   

Abstract

The distribution of the dopamine D2-receptor specific ligand iodine-123 (S)-(-)-2-hydroxy-3-iodo-6-methoxy-N[(1-ethyl-2- pyrrolidinyl)methyl]-benzamide (123I-IBZM) was investigated in human adults from whole-body scans, blood samples and urine collected up to 48 h after injection. Results from the present study performed in six healthy volunteers were combined with those of five volunteers from a previous study. Using the brain, liver, lungs and spleen as source organs, the MIRD method was applied to calculate the absorbed radiation dose of the radioligand in various organs. The thyroid (despite blockage), gallbladder wall, large intestinal walls and spleen received the highest absorbed doses. The average effective dose equivalent of 123I-IBZM for adults was estimated to be 0.034 mSv/MBq. The absorbed dose to the thyroid may be a limiting factor for 123I-IBZM studies in children.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223767     DOI: 10.1007/bf00180903

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  14 in total

1.  Population radiation absorbed dose from nuclear medicine procedures in The Netherlands.

Authors:  H Beekhuis
Journal:  Health Phys       Date:  1988-03       Impact factor: 1.316

2.  Use of ionizing radiation and radionuclides on human beings for medical research, training, and nonmedical purposes. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1977

3.  Dose to the fetus from radionuclides in the bladder.

Authors:  R J Cloutier; S A Smith; E E Watson; W S Snyder; G G Warner
Journal:  Health Phys       Date:  1973-08       Impact factor: 1.316

4.  In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans.

Authors:  H F Kung; A Alavi; W Chang; M P Kung; J W Keyes; M G Velchik; J Billings; S Pan; R Noto
Journal:  J Nucl Med       Date:  1990-05       Impact factor: 10.057

5.  Potential neuroleptic agents. 3. Chemistry and antidopaminergic properties of substituted 6-methoxysalicylamides.

Authors:  T de Paulis; Y Kumar; L Johansson; S Rämsby; L Florvall; H Hall; K Angeby-Möller; S O Ogren
Journal:  J Med Chem       Date:  1985-09       Impact factor: 7.446

6.  Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia.

Authors:  L S Pilowsky; D C Costa; P J Ell; R M Murray; N P Verhoeff; R W Kerwin
Journal:  Lancet       Date:  1992-07-25       Impact factor: 79.321

7.  Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine-123-IBZM.

Authors:  J P Seibyl; S W Woods; S S Zoghbi; R M Baldwin; H M Dey; A W Goddard; Y Zea-Ponce; G Zubal; M Germine; E O Smith
Journal:  J Nucl Med       Date:  1992-11       Impact factor: 10.057

8.  Population characteristics and absorbed dose to the population from nuclear medicine: United States--1982.

Authors:  F A Mettler; J H Christie; A G Williams; R D Moseley; C A Kelsey
Journal:  Health Phys       Date:  1986-05       Impact factor: 1.316

9.  Dynamic SPECT in two healthy volunteers to determine the optimal time for in vivo D2 dopamine receptor imaging with 123I-IBZM using the rotating gamma camera.

Authors:  N P Verhoeff; T Brücke; I Podreka; M Bobeldijk; P Angelberger; E A Van Royen
Journal:  Nucl Med Commun       Date:  1991-08       Impact factor: 1.690

10.  In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain.

Authors:  N P Verhoeff; M Bobeldijk; M G Feenstra; G J Boer; M A Maas; E Erdtsieck-Ernste; K de Bruin; E A van Royen
Journal:  Int J Rad Appl Instrum B       Date:  1991
View more
  1 in total

1.  EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2.

Authors:  Koen Van Laere; Andrea Varrone; Jan Booij; Thierry Vander Borght; Flavio Nobili; Ozlem L Kapucu; Zuzana Walker; Kjell Någren; Klaus Tatsch; Jacques Darcourt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.